Literature DB >> 17955486

Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element.

Sytse J Piersma1, Marij J P Welters, Jeanette M van der Hulst, Judith N Kloth, Kitty M C Kwappenberg, Baptist J Trimbos, Cornelis J M Melief, Bart W Hellebrekers, Gert Jan Fleuren, Gemma G Kenter, Rienk Offringa, Sjoerd H van der Burg.   

Abstract

Human papillomavirus (HPV)-induced malignancies are frequently infiltrated by lymphocytes. To comprehend the contribution of HPV-specific T cells in this anti-tumor response we developed a method that allowed the analysis of the presence and specificity of cervix-infiltrating and draining lymph node resident T cells in a group of 74 patients with cervical malignancies, 54 of which were induced by HPV16 or HPV18. We detected the presence of HPV16 or HPV18-specific T cells in at least 23 of the 54 HPV-16 or -18 positive patients, and not in the 20 controls. Detailed studies resulted in the identification of 17 novel CD4+ and CD8+ T cell epitopes and their HLA-restriction elements, and also revealed that the HPV-specific immune response was aimed at both E6 and E7 and showed no preferential recognition of immunodominant regions. Unexpectedly, the vast majority of the CD4+ T cell epitopes were presented in the context of the less abundantly expressed HLA-DQ and HLA-DP molecules. Since the identified T cell epitopes constitute physiological targets in the immune response to HPV16 and HPV18 positive tumors they will be valuable for detailed studies on the interactions between the tumor and the immune system. This is crucial for the optimization of cancer immunotherapy in patients with pre-existing tumor-immunity. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17955486     DOI: 10.1002/ijc.23162

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

1.  A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.

Authors:  Sanja Stevanović; Sarah R Helman; John R Wunderlich; Michelle M Langhan; Stacey L Doran; Mei Li M Kwong; Robert P T Somerville; Christopher A Klebanoff; Udai S Kammula; Richard M Sherry; James C Yang; Steven A Rosenberg; Christian S Hinrichs
Journal:  Clin Cancer Res       Date:  2018-12-05       Impact factor: 12.531

2.  NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.

Authors:  Nadine van Montfoort; Linda Borst; Michael J Korrer; Marjolein Sluijter; Koen A Marijt; Saskia J Santegoets; Vanessa J van Ham; Ilina Ehsan; Pornpimol Charoentong; Pascale André; Nicolai Wagtmann; Marij J P Welters; Young J Kim; Sytse J Piersma; Sjoerd H van der Burg; Thorbald van Hall
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

3.  A Human Papillomavirus Type 16 E6 52-62 CD4 T-Cell Epitope Restricted by the HLA-DR11 Molecule Described in an Epitope Hotspot.

Authors:  Hannah N Coleman; Xuelian Wang; William W Greenfield; Mayumi Nakagawa
Journal:  MOJ Immunol       Date:  2014

4.  CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.

Authors:  Samantha Seresini; Massimo Origoni; Luigi Caputo; Flavia Lillo; Renato Longhi; Simone Vantini; Anna Maria Paganoni; Maria Pia Protti
Journal:  Immunology       Date:  2010-06-02       Impact factor: 7.397

5.  Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.

Authors:  Marij J P Welters; Gemma G Kenter; Peggy J de Vos van Steenwijk; Margriet J G Löwik; Dorien M A Berends-van der Meer; Farah Essahsah; Linda F M Stynenbosch; Annelies P G Vloon; Tamara H Ramwadhdoebe; Sytse J Piersma; Jeanette M van der Hulst; A Rob P M Valentijn; Lorraine M Fathers; Jan W Drijfhout; Kees L M C Franken; Jaap Oostendorp; Gert Jan Fleuren; Cornelis J M Melief; Sjoerd H van der Burg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

Review 6.  Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines.

Authors:  Mayumi Nakagawa; William Greenfield; Andrea Moerman-Herzog; Hannah N Coleman
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

7.  A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.

Authors:  Angelika B Riemer; Derin B Keskin; Guanglan Zhang; Maris Handley; Karen S Anderson; Vladimir Brusic; Bruce Reinhold; Ellis L Reinherz
Journal:  J Biol Chem       Date:  2010-07-08       Impact factor: 5.157

Review 8.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic.

Authors:  Max Corbett; Willy M Bogers; Jonathan L Heeney; Stefan Gerber; Christian Genin; Arnaud Didierlaurent; Herman Oostermeijer; Rob Dubbes; Gerco Braskamp; Stéphanie Lerondel; Carmen E Gomez; Mariano Esteban; Ralf Wagner; Ivanella Kondova; Petra Mooij; Sunita Balla-Jhagjhoorsingh; Niels Beenhakker; Gerrit Koopman; Sjoerd van der Burg; Jean-Pierre Kraehenbuhl; Alain Le Pape
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-11       Impact factor: 11.205

10.  Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.

Authors:  I Bourgault Villada; M Moyal Barracco; S Berville; M L Bafounta; C Longvert; V Prémel; P Villefroy; E Jullian; T Clerici; B Paniel; B Maillère; J Choppin; J G Guillet
Journal:  Clin Exp Immunol       Date:  2009-07-30       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.